The Prelude Drug Discovery Engine has been purpose-built to accelerate the process of identifying novel medicines that have the potential to improve the lives of cancer patients. Our goal is to pursue deeper insights into precision oncology therapeutics, while constantly challenging each of our ideas, so we can achieve better patient outcomes for unmet medical needs in Oncology.
How Do We Move So Fast from Idea to IND?
Our cancer biology team provides a roadmap for an optimal product profile and our medicinal chemists design and build molecules to meet those criteria. The team rapidly iterates the design, synthesis, and testing of typically 500-1000 novel molecules using state-of-the art modeling, chemical methodologies and automated processes over the course of 12 to 18 months. The success of our Discovery engine can be seen in our six clinical candidates internally discovered from idea to IND in the past 6 years.
Prelude’s Drug Discovery and Development Approach
Our broad cancer biology and medicinal chemistry expertise across small molecule inhibitors and targeted protein degraders allows us a highly flexible approach to target selection. Thus, our focus can be on addressing the most significant unmet needs for cancer patients and discovering and developing the highest quality clinical candidates. We prioritize the selection of new targets based on three primary criteria:
- Targets that drive cancers with high unmet need
- Targets with compelling biological rationale and validation
- Targets with challenging medicinal chemistry problems
